{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-069993","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.513478+00:00","generated_at":"2026-06-14T03:51:19.532061+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Pfizer terminates global license deal for Theravance's preclinical JAK inhibitor","bullets":["Termination effective Oct 7, 2023; Pfizer gave notice June 9, 2023.","Agreement covered preclinical skin-selective, locally acting pan-JAK inhibitor program.","No reason for termination or financial impact disclosed by Theravance.","Theravance regains rights to the program subject to wind-down obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-069993","json":"https://secwatch.observer/filing/0001104659-23-069993.json","markdown":"https://secwatch.observer/filing/0001104659-23-069993.md","text":"https://secwatch.observer/filing/0001104659-23-069993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923069993/0001104659-23-069993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923069993/tm2318324d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:51:19.532061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ff72a74e54b98a6cfc9781c06a36281c58242b2","claim":"Theravance Biopharma, Inc. terminated Pfizer Agreement with Pfizer Inc. (effective 2023-10-07).","evidence_excerpt":"On June 9 , 2023, the Company received notice from Pfizer terminating the Pfizer Agreement, effective as of October 7, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923069993/0001104659-23-069993-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Pfizer Inc."},{"label":"Effective","value":"2023-10-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}